Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten Urothelkarzinom: Eine randomisierte, kontrollierte Phase-III-Studie zum Vergleich von Pembrolizumab mit und ohne platinbasierter Kombinationschemotherapie und der alleinigen Chemotherapie bei Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom (Keynote-361 – AB 54/16 der AUO)

Translated title of the contribution: First-line therapy for locally advanced or metastatic urothelial carcinoma: A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361—AB 54/16 of the AUO)

H. Rexer, C. H. Ohlmann, M. Retz

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Translated title of the contributionFirst-line therapy for locally advanced or metastatic urothelial carcinoma: A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361—AB 54/16 of the AUO)
Original languageGerman
Pages (from-to)659-661
Number of pages3
JournalUrologe - Ausgabe A
Volume56
Issue number5
DOIs
StatePublished - 1 May 2017
Externally publishedYes

Cite this